← Back to Clinical Trials
Recruiting NCT02748226

NCT02748226 Korean Vascular Intervention Society Multicenter Registry Study on Outcomes of Endovascular Therapy in Lower Limb Artery Diseases (K-VIS ELLA): (A Retrospective & Prospective Observational Study)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT02748226
Status Recruiting
Phase
Sponsor Yonsei University
Condition Peripheral Arterial Disease(PAD)
Study Type OBSERVATIONAL
Enrollment 12,000 participants
Start Date 2013-09-30
Primary Completion 2032-07-31

Trial Parameters

Condition Peripheral Arterial Disease(PAD)
Sponsor Yonsei University
Study Type OBSERVATIONAL
Phase N/A
Enrollment 12,000
Sex ALL
Min Age 20 Years
Max Age N/A
Start Date 2013-09-30
Completion 2032-07-31
Interventions
endovascular treatment

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

1. Study design: multicenter retrospective and prospective observational study 2. Study Cohort : 1. Retrospective cohort: This cohort retrospectively enrolls patients with lower extremity artery disease who underwent endovascular treatment from January 2006 to the date of approval by IRB in the participating hospitals. Informed consent was waived by IRB. 2. Prospective cohort: This cohort prospectively enrolls patients with lower extremity artery disease who undergo endovascular treatment from the date of approval by IRB to July, 2018 in the participating hospitals. Informed consent will be obtained prior to enrollment. 3. Baseline clinical and lesion characteristics, procedural and post-procedural data, clinical outcomes, hemodynamic, and imaging follow-up data are investigated. Primary patency and target lesion revascularization rates of the total cohort and patient subgroups are evaluated. Risk factors of restenosis and target lesion revascularization are determined.

Eligibility Criteria

Inclusion Criteria: * Retrospective data Patients who underwent or attempted endovascular treatment for symptomatic peripheral artery disease from January 2006 until IRB approval date * Prospective data 1. Age 20 years of older 2. Patients in the treatment or trying about symptomatic peripheral artery disease from IRB approval date 3. Symptomatic peripheral artery disease: * Intermittent claudication (Rutherford category 1 to 3) * Critical limb ischemia (Rutherford category 4 to 6) Exclusion Criteria: 1. Pregnant women or women with potential childbearing 2. Moderate Alzheimer's disease, mental illness or neurological disease of more than those who can not understand the purpose of this clinical trials and Methods 3. Life expectancy \<1 year due to comorbidity

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology